Three peptides, one instruction and one hormone built to refuse it

This is the written version of CJC-1295, Ipamorelin, Sermorelin: The Catch In All Three — watch it instead if you’d rather.

CJC-1295, Ipamorelin and Sermorelin get lumped together so often that it is easy to assume they are basically the same product sold three ways. They are not. Each one pulls on your endocrine system through a genuinely different route. But strip away the branding and all three run into the identical obstacle, because none of them puts growth hormone into your body. Every one of them is a request, addressed to your own pituitary gland, asking it to release more of its own. And your body employs a hormone whose entire job is to turn that request down.

Three requests, not three deliveries

Growth hormone does not leak out of the pituitary at a steady drip. It is released in bursts, mostly overnight, under the control of two opposing signals: growth-hormone-releasing hormone (GHRH) pushes the release forward, and somatostatin holds it back. Sermorelin and CJC-1295 both work by mimicking GHRH itself — they are built from the business end of the same natural molecule. Ipamorelin does something else entirely: it mimics ghrelin, the hunger hormone, and acts on a separate receptor to trigger the same release through a different door. Three different levers, sure. But every single one of them ends at the same request — make more of your own GH — not at a syringe full of the finished hormone.

Sermorelin: the original, short-lived request

Sermorelin is essentially a copy of the first 29 amino acids of human GHRH — the fragment that actually does the work of triggering release. One review describes it working exactly the way your own GHRH does: through the body's natural, pulsatile pattern, tested in adults with diagnosed growth hormone insufficiency, not in healthy people chasing a look. It was, at one point, sold as an approved prescription product under the name Geref. The manufacturer later stopped making it. When the FDA formally reviewed that withdrawal years afterwards, its determination was specific: Geref was not pulled from sale for reasons of safety or effectiveness. That is a commercial decision being confirmed as a commercial decision, not a hidden safety story.

CJC-1295: the same request that refuses to let go

CJC-1295 starts as the same idea as Sermorelin — a modified GHRH fragment — with one addition: a piece that latches onto albumin, a carrier protein that is already circulating in your blood in enormous quantities. Bonded to it, the peptide gets to ride around on the body's own long-lived transport system instead of being broken down in minutes. The one human pharmacokinetic study of the compound found a half-life of roughly 5.8 to 8.1 days, with growth hormone rising several-fold and IGF-1 climbing alongside it. It was a small study, and it was funded by the company that developed the compound, so treat the exact multiples as a single data point rather than a settled fact. The mechanism, though, is where the catch actually lives: that same study found the elevation was sustained rather than pulsatile. Remember that GH is only supposed to arrive in bursts. A version that keeps the request open for the better part of a week is not a bigger version of the natural pattern — it is a different pattern altogether, closer to the low, constant flood seen in acromegaly than to the natural rhythm it is supposedly restoring.

Ipamorelin: a cleaner request, not an exemption

Ipamorelin's reputation is built on being the tidy one. Earlier compounds in its family also pushed up ACTH, cortisol and prolactin alongside growth hormone — a noisier signal than anyone wanted. The study that first characterised ipamorelin found it released growth hormone while largely leaving those other hormones alone, making it the first selective compound of its kind. That selectivity is real and it matters. What it does not do is exempt ipamorelin from the underlying arrangement. It still works by asking the pituitary to release GH it would otherwise be holding back, through a lever your body did not intend to be pulled this deliberately or this often. Clean is not the same as free of consequence.

The catch that runs through all three

This is the part the marketing skips: your body did not design somatostatin as an afterthought. It is the counterweight to GHRH, and it exists precisely to stop growth hormone release from running away with itself. Whichever lever you pull — a short natural-pattern nudge, a long-acting version that will not switch off, or a completely separate ghrelin-pathway trigger — you are pushing against a system built to resist exactly that kind of pressure. That is the catch shared by all three compounds, and it is a mechanical one, not a branding problem: they ask, and something in the same system is built to say no back.

Where the paperwork actually stands

The regulatory picture is easy to overstate in either direction, so I will stick to what is actually on the record. Ipamorelin acetate appears on the FDA's list of bulk drug substances that may present significant safety risks for compounding — the so-called Category 2 list — specifically under the column covering 503B outsourcing facilities. That is a formal caution flag sitting in a specific regulatory lane, not a verdict on the compound's biology. Sermorelin's history, meanwhile, is the opposite kind of caution: an approved product that a manufacturer simply stopped making, later confirmed by the FDA itself as a business decision rather than a safety one. Neither of those facts tells you anything about how a given research product sold today was made, tested, or handled before it reached anyone's fridge — and the human evidence behind the muscle-and-recovery claims made about all three remains thin relative to how confidently it gets repeated. I have written separately about just how thin that evidence base tends to be across the category, in why a peptide might not be working the way you expected.

They do not hand your body growth hormone. They ask for it — and something in the same system is built to say no.

The bottom line

Sermorelin, CJC-1295 and Ipamorelin are three different engineering solutions to the same problem: how to make the pituitary release more of its own growth hormone. One is the short-lived original that fell out of production for business reasons, not safety ones. One rides a carrier protein and turns a pulsed system into a sustained one. One finds a cleaner second lever without changing the arrangement underneath it. All three are requests, and all three run headlong into somatostatin, the brake your body evolved specifically to stop this kind of push from going unchecked. Understanding that shared catch is worth more than memorising which peptide does what — it is the reason none of these are a shortcut, however they are pulled. For what it is worth, I take no money from anybody who sells peptides; if you want the fuller background on the category, there are three free guides that go further than one article can.

Sources

1. Teichman et al., J Clin Endocrinol Metab, 2006 — the one human pharmacokinetic study of CJC-1295: a half-life of 5.8 to 8.1 days, growth hormone up several-fold and IGF-1 up alongside it, held at a sustained rather than pulsatile level. A small study, and funded by the compound’s developer — https://doi.org/10.1210/jc.2005-1536
2. Jetté et al., Endocrinology, 2005 — the mechanism behind that half-life: CJC-1295 is a modified fragment of growth-hormone-releasing hormone bonded to serum albumin, so it rides the body’s own long-lived carrier protein — https://doi.org/10.1210/en.2004-1286
3. Raun et al., European Journal of Endocrinology, 1998 — ipamorelin as the first selective growth hormone secretagogue: it releases growth hormone without the rises in ACTH, cortisol and prolactin that the earlier GHRPs produced — https://doi.org/10.1530/eje.0.1390552
4. Walker, Clinical Interventions in Aging, 2006 — sermorelin as a GHRH analogue working through the body’s natural pulsatile release, in adult growth hormone insufficiency — https://doi.org/10.2147/ciia.2006.1.4.307
5. Federal Register, 4 March 2013 — the FDA’s formal determination that GEREF (sermorelin acetate) injection was NOT withdrawn from sale for reasons of safety or effectiveness — https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams
6. FDA, Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks — the Category 2 list. Ipamorelin acetate sits on it, under the 503B outsourcing-facility column — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

Educational and research purposes only — not medical advice. Peptide Corner does not recommend any vendor, source, or dose. Keep safe, keep skeptical.